查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1877786

2025年全球體外癌症診斷市場報告

In Vitro Cancer Diagnostics Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年來，體外癌症診斷市場規模顯著成長，預計將從2024年的106.8億美元成長到2025年的114.9億美元，複合年成長率（CAGR）為7.5%。過去幾年的成長可歸因於癌症發病率的上升、患者對癌症早期檢測意識的增強、分子診斷技術的日益普及、醫療基礎設施投資的增加以及對癌症診斷生物標記發現研究的日益重視。

預計未來幾年體外癌症診斷市場規模將強勁成長，2029年將達到155.4億美元，複合年成長率（CAGR）為7.8%。預測期內的成長將主要受以下因素驅動：腫瘤學領域對個人化醫療的需求不斷成長、照護現場癌症診斷需求不斷成長、人們對微創檢測方法的認知不斷提高、對生物技術和診斷Start-Ups的投資不斷增加，以及對經濟高效的診斷解決方案的需求不斷成長。預測期內的關鍵趨勢包括液態生物檢體技術的進步、與人工智慧的融合、微流體平台的創新、數位病理系統的發展以及基因組數據分析的進步。

預計未來幾年，液態生物檢體技術的日益普及將推動體外癌症診斷市場的成長。液態生物檢體技術是一種微創診斷方法，它能夠檢測和分析存在於血液、尿液和唾液等體液中的生物標記物，例如循環腫瘤DNA、循環性腫瘤細胞和外泌體，從而監測疾病（尤其是癌症）的存在、進展和治療反應。從血液和其他體液中分離和分析循環腫瘤DNA和循環性腫瘤細胞的技術進步促進了液態生物檢體技術的擴展。液態生物檢體技術的快速普及正在推動對體外癌症診斷解決方案的需求，因為用於癌症檢測和治療指導的非侵入性即時分子分析工具正被擴大採用。例如，據英國國家醫療服務體系（NHS England）稱，到2025年5月，英國新推出的液態生物檢體血液檢測預計每年將使多達15,000名疑似肺癌患者和5,000名進行性乳癌女性患者受益。預計檢測對象數量將從2025年初推出時的約2,200人增加到2028年的每年約20,000人。因此，液態生物檢體技術的日益普及正在推動體外癌症診斷市場的成長。

體外癌症診斷市場的主要企業正致力於開發人工智慧驅動的癌症診斷技術，旨在改善患者預後並促進個人化醫療。人工智慧驅動的癌症診斷利用人工智慧分析從患者檢體、影像和基因檢測中獲得的醫學和分子數據，從而實現高度精準的癌症檢測、診斷和預測。例如，總部位於瑞士的製藥公司羅氏於2024年9月推出了數位病理開放環境（Digital Pathology Open Environment），這是一個協作平台，安全地整合了羅氏和多家第三方開發商的先進人工智慧影像分析工具。該平台使病理學家能夠存取羅氏Navifify數位病理企業軟體中的創新演算法，從而提高診斷準確性和工作流程效率。透過促進協作和數據共用，該平台加速了癌症診斷和監測領域的創新，支持精準醫療，實現了更有效的標靶治療，並擴大了全球先進數位病理解決方案的獲取途徑。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通貨膨脹、地緣政治、貿易戰和關稅，以及新冠疫情及其復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球體外癌症診斷市場：PESTEL 分析（政治、社會、技術、環境、法律因素、促進因素與限制因素）
  • 終端用戶產業分析
  • 全球體外癌症診斷市場：成長率分析
  • 全球體外癌症診斷市場表現：規模與成長，2019-2024年
  • 全球體外癌症診斷市場預測：規模與成長，2024-2029年，2034年預測
  • 全球體外癌症診斷市場：潛在市場規模（TAM）

第6章 市場細分

  • 全球體外癌症診斷市場：依產品類型、效能和預測分類，2019-2024年、2024-2029年預測、2034年預測
  • 成套工具
  • 裝置
  • 試劑
  • 軟體
  • 消耗品
  • 全球體外癌症診斷市場：依技術、效能和預測分類，2019-2024年、2024-2029年預測、2034年預測
  • 聚合酵素鏈鎖反應（PCR）
  • 次世代定序（NGS）
  • 螢光原位雜合反應（FISH）
  • 免疫組織化學
  • 其他技術
  • 全球體外癌症診斷市場：依應用、效能和預測分類，2019-2024年、2024-2029年預測、2034年預測
  • 乳癌
  • 肺癌
  • 大腸直腸癌
  • 攝護腺癌
  • 其他用途
  • 全球體外癌症診斷市場：依最終用戶、效能和預測分類，2019-2024年、2024-2029年預測、2034年預測
  • 醫院
  • 診斷檢查室
  • 研究所
  • 居家醫療環境
  • 其他最終用戶
  • 全球體外癌症診斷市場：依試劑盒、類型、效能和預測細分，2019-2024年、2024-2029年預測、2034年預測
  • 免疫檢測盒
  • 聚合酵素鏈鎖反應(PCR) 試劑盒
  • 酵素免疫分析法（ELISA）試劑盒
  • 流式細胞技術盒
  • 全球體外癌症診斷市場：按設備、類型、性能和預測進行細分，2019-2024年、2024-2029年預測、2034年預測
  • 聚合酵素鏈鎖反應（PCR）設備
  • 序列器
  • 流式細胞儀
  • 影像系統
  • 全球體外癌症診斷市場：依試劑、類型、效能和預測細分，2019-2024年、2024-2029年預測、2034年預測
  • 酵素
  • 緩衝
  • 探測
  • 染料
  • 全球體外癌症診斷市場：依軟體、類型、效能和預測細分，2019-2024年、2024-2029年預測、2034年預測
  • 數據分析軟體
  • 影像處理軟體
  • 實驗室資訊管理系統（LIMS）軟體
  • 診斷報告軟體
  • 全球體外癌症診斷市場：按耗材、類型、性能和預測細分，2019-2024年、2024-2029年預測、2034年預測
  • 微孔盤
  • 微量吸管尖
  • 管子
  • 滑動

第7章 區域和國家分析

  • 全球體外癌症診斷市場：依地區、績效及預測分類，2019-2024年、2024-2029年預測、2034年預測
  • 全球體外癌症診斷市場：依國家、績效及預測分類，2019-2024 年、2024-2029 年預測、2034 年預測

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章：澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章 西歐市場

第16章英國市場

第17章：德國市場

第18章：法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章：俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章：競爭格局與公司概況

  • 體外癌症診斷市場：競爭格局
  • 體外癌症診斷市場：公司概況
    • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
    • Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis
    • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • Thermo Fisher Scientific Overview, Products and Services, Strategy and Financial Analysis
    • Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis

第31章：其他領先和創新企業

  • Illumina Inc
  • Hologic Inc
  • Qiagen NV
  • Bio-Rad Laboratories Inc
  • Agilent Technologies
  • Becton Dickinson and Company（BD）
  • Sysmex Corporation
  • LabCorp Holding Corp.
  • Guardant Health
  • Quest Diagnostics
  • Exact Sciences
  • Myriad Genetics Inc
  • Natera Inc.
  • NeoGenomics Laboratories
  • NanoString Technologies Inc

第32章 全球市場競爭基準化分析與儀錶板

第33章 重大併購

第34章 近期市場趨勢

第35章：高潛力市場國家、細分市場與策略

  • 2029年體外癌症診斷市場：提供新機會的國家
  • 2029年體外癌症診斷市場：新興細分市場機會
  • 2029年體外癌症診斷市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第36章附錄

簡介目錄
Product Code: r39261

In vitro cancer diagnostics refers to laboratory-based tests conducted on samples such as blood, tissue, or other body fluids to detect, monitor, or evaluate cancer outside the human body. These diagnostics employ techniques like molecular assays, biomarker analysis, and genetic profiling to identify the presence or progression of cancer. They support early detection, accurate diagnosis, and informed treatment planning for patients.

The key product types in in vitro cancer diagnostics include kits, instruments, reagents, software, and consumables. Kits are ready-to-use sets of reagents and materials designed for diagnostic testing, enabling biomarker detection, supporting disease monitoring, and assisting in treatment evaluation. Technologies used include polymerase chain reaction (PCR), next-generation sequencing (NGS), fluorescence in situ hybridization (FISH), immunohistochemistry, and others. These diagnostics are applied across multiple cancer types, including breast cancer, lung cancer, colorectal cancer, and prostate cancer, and serve end users such as hospitals, diagnostic laboratories, research institutes, home care settings, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers' margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

The in vitro cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides in vitro cancer diagnostics market statistics, including in vitro cancer diagnostics industry global market size, regional shares, competitors with a in vitro cancer diagnostics market share, detailed in vitro cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the in vitro cancer diagnostics industry. This in vitro cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The in vitro cancer diagnostics market size has grown strongly in recent years. It will grow from $10.68 billion in 2024 to $11.49 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth observed during the historical period can be attributed to the rising prevalence of cancer, heightened awareness among patients regarding early cancer detection, increased adoption of molecular diagnostic techniques, expanded investments in healthcare infrastructure, and a growing focus on research in biomarker discovery for cancer diagnostics.

The in vitro cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $15.54 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth during the forecast period is driven by the increasing demand for personalized medicine in oncology, rising demand for point-of-care cancer diagnostics, growing awareness of minimally invasive testing methods, increasing investment in biotech and diagnostic startups, and rising need for cost-effective diagnostic solutions. Primary trends in the forecast period include advancements in liquid biopsy technology, integration with artificial intelligence, innovation in microfluidics platforms, development of digital pathology systems, and progress in genomic data analysis.

The rising adoption of liquid biopsy technologies is expected to enhance the growth of the in vitro cancer diagnostics market in the coming years. Liquid biopsy technologies refer to minimally invasive diagnostic methods that detect and analyze biomarkers such as circulating tumor DNA, circulating tumor cells, or exosomes present in body fluids like blood, urine, or saliva to monitor disease presence, progression, or response to treatment, particularly in cancer. The use of liquid biopsy technologies is increasing due to advancements in isolating and analyzing circulating tumor DNA and circulating tumor cells from blood and other body fluids. In vitro cancer diagnostic solutions are experiencing higher demand as the rapid adoption of liquid biopsy technologies encourages companies to implement non invasive and real time molecular profiling tools for cancer detection and treatment guidance. For example, in May 2025, according to NHS England, a UK based public healthcare system, the new liquid biopsy blood test rollout in the UK is expected to benefit up to 15,000 patients with suspected lung cancer and 5,000 women with advanced breast cancer annually, expanding from about 2,200 patients tested during the early 2025 rollout to an estimated 20,000 patients per year by 2028. Therefore, the rising adoption of liquid biopsy technologies is enhancing the growth of the in vitro cancer diagnostics market.

Leading companies operating in the in vitro cancer diagnostics market are emphasizing the development of AI-driven cancer diagnostics to improve patient outcomes and advance personalized healthcare. AI-driven cancer diagnostics involve the use of artificial intelligence to analyze medical and molecular data from patient samples, imaging, or genetic tests, enabling highly accurate detection, diagnosis, and prediction of cancer. For instance, in September 2024, Roche, a Switzerland-based pharmaceutical company, introduced the Digital Pathology Open Environment, a collaborative platform that securely integrates advanced AI-based image analysis tools from Roche and multiple third-party developers. The platform allows pathologists to access innovative algorithms within Roche's Navify Digital Pathology enterprise software, enhancing diagnostic precision and workflow efficiency. By fostering collaboration and data sharing, the platform accelerates innovation in cancer diagnostics and research, supports precision medicine, and enables more effective targeted treatments, expanding global access to advanced digital pathology solutions.

In February 2024, Veracyte Inc., a US-based molecular diagnostics company, acquired C2i Genomics, Inc. for an undisclosed amount. Through this acquisition, Veracyte aims to expand its presence across the cancer care continuum by incorporating AI-driven whole-genome minimal residual disease testing to enhance treatment monitoring and detect disease recurrence. C2i Genomics Inc. is a US-based biotechnology company that provides in vitro cancer diagnostics.

Major players operating in the in vitro cancer diagnostics market are F. Hoffmann-La Roche Ltd, Danaher Corporation, Abbott Laboratories, Thermo Fisher Scientific, Siemens Healthineers AG, Illumina Inc, Hologic Inc, Qiagen N.V, Bio-Rad Laboratories Inc, Agilent Technologies, Becton, Dickinson and Company (BD), Sysmex Corporation, LabCorp Holding Corp., Guardant Health, Quest Diagnostics, Exact Sciences, Myriad Genetics Inc, Natera Inc., NeoGenomics Laboratories, NanoString Technologies Inc, Caris Life Sciences, Transasia Bio-Medicals Ltd, Autobio Diagnostics Co Ltd, QuidelOrtho Corporation, Cancer Diagnostics Inc, Predicine Inc, Strata Oncology, Biocept Inc, Lucence Diagnostics

North America was the largest region in the in vitro cancer diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in vitro cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the in vitro cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The in vitro cancer diagnostics market consists of revenues earned by entities by providing services such as molecular diagnostic testing, biopsy and cytology analysis, companion diagnostic services, and next-generation sequencing (NGS) services. The market value includes the value of related goods sold by the service provider or included within the service offering. The in vitro cancer diagnostics market also includes sales of cancer biomarker kits, molecular diagnostic assays, flow cytometry kits, tissue-based diagnostic kits, and genomic testing panels. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

In Vitro Cancer Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on in vitro cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for in vitro cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The in vitro cancer diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product Type: Kits; Instruments; Reagents; Software; Consumables
  • 2) By Technology: Polymerase Chain Reaction (PCR); Next-Generation Sequencing (NGS); Fluorescence In Situ Hybridization (FISH); Immunohistochemistry; Other Technologies
  • 3) By Application: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Other Applications
  • 4) By End User: Hospitals; Diagnostic Laboratories; Research Institutes; Home Care Settings; Other End Users
  • Subsegments:
  • 1) By Kits: Immunoassay Kits; Polymerase Chain Reaction (PCR) Kits; Enzyme-Linked Immunosorbent Assay (ELISA) Kits; Flow Cytometry Kits
  • 2) By Instruments: Polymerase Chain Reaction (PCR) Instruments; Sequencers; Flow Cytometers; Imaging Systems
  • 3) By Reagents: Enzymes; Buffers; Probes; Stains
  • 4) By Software: Data Analysis Software; Imaging Software; Laboratory Information Management System (LIMS) Software; Diagnostic Reporting Software
  • 5) By Consumables: Microplates; Pipette Tips; Tubes; Slides
  • Companies Mentioned: F. Hoffmann-La Roche Ltd, Danaher Corporation, Abbott Laboratories, Thermo Fisher Scientific, Siemens Healthineers AG, Illumina Inc, Hologic Inc, Qiagen N.V, Bio-Rad Laboratories Inc, Agilent Technologies, Becton, Dickinson and Company (BD), Sysmex Corporation, LabCorp Holding Corp., Guardant Health, Quest Diagnostics, Exact Sciences, Myriad Genetics Inc, Natera Inc., NeoGenomics Laboratories, NanoString Technologies Inc, Caris Life Sciences, Transasia Bio-Medicals Ltd, Autobio Diagnostics Co Ltd, QuidelOrtho Corporation, Cancer Diagnostics Inc, Predicine Inc, Strata Oncology, Biocept Inc, Lucence Diagnostics
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. In Vitro Cancer Diagnostics Market Characteristics

3. In Vitro Cancer Diagnostics Market Trends And Strategies

4. In Vitro Cancer Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global In Vitro Cancer Diagnostics Growth Analysis And Strategic Analysis Framework

  • 5.1. Global In Vitro Cancer Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global In Vitro Cancer Diagnostics Market Growth Rate Analysis
  • 5.4. Global In Vitro Cancer Diagnostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global In Vitro Cancer Diagnostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global In Vitro Cancer Diagnostics Total Addressable Market (TAM)

6. In Vitro Cancer Diagnostics Market Segmentation

  • 6.1. Global In Vitro Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Kits
  • Instruments
  • Reagents
  • Software
  • Consumables
  • 6.2. Global In Vitro Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Fluorescence In Situ Hybridization (FISH)
  • Immunohistochemistry
  • Other Technologies
  • 6.3. Global In Vitro Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Other Applications
  • 6.4. Global In Vitro Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Diagnostic Laboratories
  • Research Institutes
  • Home Care Settings
  • Other End Users
  • 6.5. Global In Vitro Cancer Diagnostics Market, Sub-Segmentation Of Kits, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Immunoassay Kits
  • Polymerase Chain Reaction (PCR) Kits
  • Enzyme-Linked Immunosorbent Assay (ELISA) Kits
  • Flow Cytometry Kits
  • 6.6. Global In Vitro Cancer Diagnostics Market, Sub-Segmentation Of Instruments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Polymerase Chain Reaction (PCR) Instruments
  • Sequencers
  • Flow Cytometers
  • Imaging Systems
  • 6.7. Global In Vitro Cancer Diagnostics Market, Sub-Segmentation Of Reagents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Enzymes
  • Buffers
  • Probes
  • Stains
  • 6.8. Global In Vitro Cancer Diagnostics Market, Sub-Segmentation Of Software, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Data Analysis Software
  • Imaging Software
  • Laboratory Information Management System (LIMS) Software
  • Diagnostic Reporting Software
  • 6.9. Global In Vitro Cancer Diagnostics Market, Sub-Segmentation Of Consumables, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Microplates
  • Pipette Tips
  • Tubes
  • Slides

7. In Vitro Cancer Diagnostics Market Regional And Country Analysis

  • 7.1. Global In Vitro Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global In Vitro Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific In Vitro Cancer Diagnostics Market

  • 8.1. Asia-Pacific In Vitro Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific In Vitro Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific In Vitro Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific In Vitro Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China In Vitro Cancer Diagnostics Market

  • 9.1. China In Vitro Cancer Diagnostics Market Overview
  • 9.2. China In Vitro Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China In Vitro Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China In Vitro Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India In Vitro Cancer Diagnostics Market

  • 10.1. India In Vitro Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India In Vitro Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India In Vitro Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan In Vitro Cancer Diagnostics Market

  • 11.1. Japan In Vitro Cancer Diagnostics Market Overview
  • 11.2. Japan In Vitro Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan In Vitro Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan In Vitro Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia In Vitro Cancer Diagnostics Market

  • 12.1. Australia In Vitro Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia In Vitro Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia In Vitro Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia In Vitro Cancer Diagnostics Market

  • 13.1. Indonesia In Vitro Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia In Vitro Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia In Vitro Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea In Vitro Cancer Diagnostics Market

  • 14.1. South Korea In Vitro Cancer Diagnostics Market Overview
  • 14.2. South Korea In Vitro Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea In Vitro Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea In Vitro Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe In Vitro Cancer Diagnostics Market

  • 15.1. Western Europe In Vitro Cancer Diagnostics Market Overview
  • 15.2. Western Europe In Vitro Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe In Vitro Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe In Vitro Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK In Vitro Cancer Diagnostics Market

  • 16.1. UK In Vitro Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK In Vitro Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK In Vitro Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany In Vitro Cancer Diagnostics Market

  • 17.1. Germany In Vitro Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany In Vitro Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany In Vitro Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France In Vitro Cancer Diagnostics Market

  • 18.1. France In Vitro Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France In Vitro Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France In Vitro Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy In Vitro Cancer Diagnostics Market

  • 19.1. Italy In Vitro Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy In Vitro Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy In Vitro Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain In Vitro Cancer Diagnostics Market

  • 20.1. Spain In Vitro Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain In Vitro Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain In Vitro Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe In Vitro Cancer Diagnostics Market

  • 21.1. Eastern Europe In Vitro Cancer Diagnostics Market Overview
  • 21.2. Eastern Europe In Vitro Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe In Vitro Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe In Vitro Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia In Vitro Cancer Diagnostics Market

  • 22.1. Russia In Vitro Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia In Vitro Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia In Vitro Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America In Vitro Cancer Diagnostics Market

  • 23.1. North America In Vitro Cancer Diagnostics Market Overview
  • 23.2. North America In Vitro Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America In Vitro Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America In Vitro Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA In Vitro Cancer Diagnostics Market

  • 24.1. USA In Vitro Cancer Diagnostics Market Overview
  • 24.2. USA In Vitro Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA In Vitro Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA In Vitro Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada In Vitro Cancer Diagnostics Market

  • 25.1. Canada In Vitro Cancer Diagnostics Market Overview
  • 25.2. Canada In Vitro Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada In Vitro Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada In Vitro Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America In Vitro Cancer Diagnostics Market

  • 26.1. South America In Vitro Cancer Diagnostics Market Overview
  • 26.2. South America In Vitro Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America In Vitro Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America In Vitro Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil In Vitro Cancer Diagnostics Market

  • 27.1. Brazil In Vitro Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil In Vitro Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil In Vitro Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East In Vitro Cancer Diagnostics Market

  • 28.1. Middle East In Vitro Cancer Diagnostics Market Overview
  • 28.2. Middle East In Vitro Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East In Vitro Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East In Vitro Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa In Vitro Cancer Diagnostics Market

  • 29.1. Africa In Vitro Cancer Diagnostics Market Overview
  • 29.2. Africa In Vitro Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa In Vitro Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa In Vitro Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. In Vitro Cancer Diagnostics Market Competitive Landscape And Company Profiles

  • 30.1. In Vitro Cancer Diagnostics Market Competitive Landscape
  • 30.2. In Vitro Cancer Diagnostics Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Thermo Fisher Scientific Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis

31. In Vitro Cancer Diagnostics Market Other Major And Innovative Companies

  • 31.1. Illumina Inc
  • 31.2. Hologic Inc
  • 31.3. Qiagen N.V
  • 31.4. Bio-Rad Laboratories Inc
  • 31.5. Agilent Technologies
  • 31.6. Becton Dickinson and Company (BD)
  • 31.7. Sysmex Corporation
  • 31.8. LabCorp Holding Corp.
  • 31.9. Guardant Health
  • 31.10. Quest Diagnostics
  • 31.11. Exact Sciences
  • 31.12. Myriad Genetics Inc
  • 31.13. Natera Inc.
  • 31.14. NeoGenomics Laboratories
  • 31.15. NanoString Technologies Inc

32. Global In Vitro Cancer Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The In Vitro Cancer Diagnostics Market

34. Recent Developments In The In Vitro Cancer Diagnostics Market

35. In Vitro Cancer Diagnostics Market High Potential Countries, Segments and Strategies

  • 35.1 In Vitro Cancer Diagnostics Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 In Vitro Cancer Diagnostics Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 In Vitro Cancer Diagnostics Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer